F-1/A: NuCana PLC Announces Offering of ADSs and Warrants to Bolster Cancer Treatment Programs

NuCana PLC plans to raise capital through an offering of American Depositary Shares (ADSs) and warrants to advance its drug discovery and development programs focused on cancer treatment.

Summary

• NuCana PLC is offering up to 12,497,768 ADSs along with Series A and Series B warrants to purchase additional ADSs.
• The offering includes pre-funded warrants as an alternative to ADSs for certain purchasers.
• Each ADS or pre-funded warrant is sold with a Series A warrant and a Series B warrant.
• The assumed combined public offering price is $0.5601 per ADS and accompanying warrants.
• The Series A warrants have an exercise price of 125% of the combined public offering price and expire five years from the issuance date.
• The Series B warrants have an exercise price of 250% of the combined public offering price and expire two and a half years from the issuance date.
• The Series B warrants include a zero exercise price option under certain conditions.
• The company intends to use the net proceeds to fund drug discovery and development programs, working capital, and other corporate purposes.
• The offering is being conducted on a reasonable best efforts basis with Laidlaw & Company (UK) Ltd. acting as the placement agent.

Sentiment

Score: 5

Explanation: The document is primarily factual, outlining the terms of the offering. While the capital raise is positive, the potential dilution and risks associated with the offering temper the overall sentiment.

Positives

• The offering will provide NuCana with additional capital to advance its drug discovery and development programs.
• The inclusion of pre-funded warrants allows the company to accommodate investors who may be subject to ownership limitations.
• The Series B warrants' zero exercise price option could incentivize warrant holders to exercise, potentially providing additional capital to the company in the future (though the company does not expect to receive any cash proceeds from the exercise of the Series B Warrants).
• The company has a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable.

Negatives

• The company may not receive any cash proceeds from the exercise of the Series B Warrants.
• Existing ADS holders will experience immediate and substantial dilution based on the assumed public offering price.
• The exercise of outstanding options will dilute shareholders and ADS holders and could decrease our ADS price.
• The Series A Warrants and Series B Warrants may not have value.
• This is a best efforts offering, no minimum amount of securities is required to be sold, and we may not raise the amount of capital we believe is required for our business plans, including our near-term business plans.
• We are selling a substantial number of ADSs in this offering, which could cause the price of our ADSs to decline.
• If the holders of the Series B Warrants elect to exercise such Series B Warrants using the zero exercise price option, our shareholders will suffer substantial dilution.
• This offering may cause the price of our ADSs to decline and fall below the minimum bid price requirement required by the Nasdaq Listing Rules, which could result in our ADSs being delisted from The Nasdaq Capital Market.

Risks

• The company's plans and business conditions could change in the future as our plans and business conditions evolve.
• The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development and commercialization efforts, the status of and results from clinical trials, any collaborations that we may enter into with third parties for our product candidates and any unforeseen cash needs.
• If we were to modify the design of any of these trials, for instance, to increase the number of patients in the trials, our costs to fund the trials could increase.
• The Placement Agent is not required to buy or sell any specific number or dollar amount of the securities.
• There is no required minimum number of securities that must be sold as a condition to completion of this offering.
• We may sell fewer than all of the securities offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the event that we do not sell an amount of securities sufficient to support our continued operations, including our near-term continued operations.
• The existence of the potential additional ADSs in the public market, or the perception that such additional ADSs may be in the market, could adversely affect the price of our ADSs.
• In addition, the Warrants contain exercise price adjustments, adjustments to increase the number of shares issuable upon exercise, and, in the case of the Series B Warrants, a zero exercise price option, which, if triggered, may cause substantial dilution.

Future Outlook

Based on our planned use of the net proceeds of this offering and our current cash and cash equivalents, we estimate that such funds will be sufficient to enable us to fund our operating expenses and capital expenditure requirements at least through 2026.

Industry Context

The announcement reflects a common strategy for clinical-stage biopharmaceutical companies to raise capital to fund ongoing research and development activities. The use of ADSs and warrants is a structure often employed to attract investors while providing potential future upside.

Comparison to Industry Standards

• Comparable companies such as Sorrento Therapeutics and Celularity have also utilized public offerings of common stock and warrants to raise capital.
• The terms of the warrants, including exercise prices and expiration dates, are generally consistent with industry standards for similar offerings.
• The best efforts underwriting arrangement is a standard practice for smaller biotech companies seeking to access capital markets.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• The company's employees and researchers will benefit from the additional funding for drug development.
• Patients may benefit from the advancement of new cancer treatments.

Next Steps

• The company will seek to complete the offering and secure the necessary funding.
• The company will work to maintain its listing on the Nasdaq Capital Market.
• The company will continue to advance its drug discovery and development programs.

Key Dates

Keywords

ADSs, warrants, NuCana, offering, cancer, treatment, Securities, Ordinary Shares, Pre-Funded Warrants, Series A Warrants, Series B Warrants